May 2, 2018
2-3 PM EST
China has become the 2nd largest med-tech market in the world. Chinese government plans to spend $125 million in healthcare market over the next three years. President Xi’s initiative from “Made in China” to “Innovate in China” will drive domestic and foreign medical device/ IVD companies’ growth in the premium market. But there are also challenges along the road to success: dynamic regulatory changes, reimbursement and distribution differences.
In the first quarter of 2018, before the disappearance of CFDA name, a few major regulations been released:
This webinar, presented by Grace Fu Palma, CEO of China Med Device, LLC, will highlight following areas:
Time will be allotted for Q&A.
About China Med Device, LLC
China Med Device, LLC provides turn-key solutions for western medical device/IVD companies to enter China with regulation and commercialization services. Our CFDA regulatory services cover strategy, premarket submission, clinical evaluation, CRO, post market compliance as well as legal agent representation. Our commercial services cover market assessment research, reimbursement, partnership, distribution qualification and management. Our management team has 100+ years of combined experience in medical device and IVD and had been involved with 1,000+ CFDA certificates, 200+ Chinese and western companies’ success.